Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PerkinElmer Expands Reagent Portfolio for Faster Identification of Epigenetic Drug Candidates

Published: Tuesday, February 07, 2012
Last Updated: Tuesday, February 07, 2012
Bookmark and Share
The company announced the launch of four new cellular assay kits to help identify and characterize possible drug candidates targeting epigenetic enzymes related to key disease states.

The new addition was unveiled at the 1st annual Society for Laboratory Automation and Screening Conference, in San Diego.

The expansion of the Epigenetic Biochemical Toolbox increases the portfolio to over 35 validated enzymatic assays for the detection of post-translational modifications of histone H3 and p53. The assays cover all the major writer and eraser enzyme families including HDACs, Sirtuins, HATs, HMTs and demethylases. This newly expanded portfolio helps researchers explore epigenetics-based therapeutic candidates for cancer and neurodegenerative disorders.

"This new addition to our epigenetics portfolio is part of a series of innovations to create a full breadth of offerings to advance personalized medicine research," said Kevin Hrusovsky, president, Life Sciences and Technology, PerkinElmer. "We are taking active steps to continue to transform PerkinElmer into one of the leading providers of technologies, services and products to enable researchers in this expanding market."

The new AlphaLISA(R) Epigenetic Cellular Detection Kits enable rapid and direct detection of endogenous modification of epigenetic marks on Histone H3, all in a one-well, no-wash assay format.

"The study of epigenetics is rapidly growing and presents opportunities for drug discovery, resulting in an increased need for high quality reagents," said Mark Roskey, vice president and general manager, Reagents, Life Sciences and Technology, PerkinElmer. "We now provide the most comprehensive reagent portfolio for epigenetic drug discovery. Our solutions are highly validated with detailed, ready-to-use protocols, and optimized for simplicity and throughput, marking our commitment to this expanding area of research."

PerkinElmer's epigenetic portfolio provides researchers access to fully validated reagents and assay development services that offer valuable time savings in the race to discover novel drug candidates. These highly specific reagents along with PerkinElmer's knowledge support for the development of epigenetic assays allow researchers to identify and characterize their lead compounds more quickly and efficiently.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PerkinElmer Collaborates with Waters on Chromatography Solutions
PerkinElmer, Inc. has announced a chromatography collaboration with Waters Corporation to deliver market leading software and premium instruments to PerkinElmer’s customers.
Wednesday, February 18, 2015
PerkinElmer, Sofie Biosciences Announce Benchtop PET Imaging Partnership
Preclinical PET imaging instruments in benchtop format help support high performance disease research, drug discovery and clinical translational applications.
Tuesday, June 10, 2014
Good Start Genetics, PerkinElmer Collaboration Expands Access to Genetic Carrier Screening Tests
Strategic agreement will broaden access to GoodStart Select™ tests to include obstetrics and gynecology and maternal fetal medicine physicians.
Monday, March 17, 2014
PerkinElmer Revenues Grow 4%
PerkinElmer, Inc. reported financial results for the fourth quarter ended December 29, 2013.
Monday, February 03, 2014
CAS and PerkinElmer Combine the Power of SciFinder and ChemBioDraw
New functionality will enable ChemBioDraw users to search in SciFinder, providing access to comprehensive content available in the CAS databases.
Tuesday, December 17, 2013
PerkinElmer Announces Strategic Alliance with Integromics
PerkinElmer becomes the sole worldwide distributor of Integromics’ software for the TIBCO Spotfire.
Tuesday, June 25, 2013
PerkinElmer to Host Revolutionaries for Global Health Summit
Company to assemble thought leaders to share pioneering personalized health research and innovations.
Wednesday, May 01, 2013
ViaCord® Collaborates with the Center for International Blood and Marrow Transplant Research®
PerkinElmer’s family cord blood banking business and international research organization collaborates to analyze quality and outcomes of cord blood stem cell units.
Wednesday, May 01, 2013
PerkinElmer and MGH Pathology Collaborate
Collaboration to develop a complete sequencing informatics system for cancer research.
Wednesday, September 12, 2012
PerkinElmer and TPM Biotech SDN. BHD. Partner to Validate Screening Application for Halal Food Products
Companies collaborate to explore potential applications of PerkinElmer’s Porcine Detection Kits and chromatography solutions for use in validating methods of testing food products for compliance with Halal certification regulations.
Tuesday, April 10, 2012
PerkinElmer Announces Collaboration with Rutgers University Cell and DNA Repository
Companies team up to enable large-scale sequencing studies through more efficient automation and improving next generation sequencing sample access.
Tuesday, February 21, 2012
PerkinElmer Announces Collaboration with Rutgers University Cell and DNA Repository
Rutgers University Cell and DNA Repository has adopted PerkinElmer’s technologies for automation of Next Generation Sequencing sample preparation.
Thursday, February 16, 2012
PerkinElmer to Acquire Caliper Life Sciences
PerkinElmer, Inc. announces that it has signed a definitive agreement to acquire Caliper Life Sciences, Inc. for a total net purchase price of approximately $600 million.
Wednesday, September 21, 2011
PerkinElmer Acquires Labtronics Inc.
The acquisition of Labtronics follows the recent purchase of informatics companies CambridgeSoft and ArtusLabs by PerkinElmer, both announced in March.
Sunday, May 22, 2011
PerkinElmer Announces Acquisition of Geospiza
The acquisition of Geospiza supports PerkinElmer’s growing offerings in Next Generation DNA Sequencing and Analysis Services, enabling researchers to explore the genomic origins of disease more effectively.
Monday, May 16, 2011
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!